HCV Treatment
AASLD 2015: Study Reveals Potential Challenges for Scaling Up Hepatitis C Therapy in the UK
- Details
- Category: HCV Treatment
- Published on Tuesday, 24 November 2015 00:00
- Written by Michael Carter
A large proportion of people with chronic hepatitis C virus (HCV) infection in the UK have comorbidities, hazardous use of drugs and alcohol, and are taking medications that could potentially interact with HCV direct-acting antivirals (DAAs), according to research presented at the 2015 AASLD Liver Meeting in San Francisco. The investigators caution that clinicians "need to be aware" of the potential for interactions when choosing HCV treatment regimens.
Coverage of the 2015 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Monday, 23 November 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.
Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.
11/23/15
AASLD 2015: Daclatasvir + Sofosbuvir Works Well for Genotype 3 HCV Patients with Advanced Disease
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 19 November 2015 00:00
- Written by Liz Highleyman
Interferon-free treatment with daclatasvir plus sofosbuvir, with or without ribavirin, led to sustained virological response in a majority of patients with genotype 3 hepatitis C virus (HCV) and advanced liver disease treated in a real-world setting in compassionate use programs in Europe, according to a pair of studies presented at the 2015 AASLD Liver Meeting this week in San Francisco.
AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 19 November 2015 00:00
- Written by Liz Highleyman
An all-oral combination of daclatasvir, sofosbuvir, and ribavirin taken for 12 or 16 weeks led to high sustained virological response rates for people with hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced liver fibrosis or cirrhosis, according to findings from the ALLY-3+ study presented at the 2015 AASLD Liver Meeting this week in San Francisco.
AASLD 2015: Intensification with Sofosbuvir Permits Cure after Previous HCV Treatment Failure
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 19 November 2015 00:00
- Written by Keith Alcorn
Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir (Sovaldi), a pair of studies presented at the AASLD Liver Meeting this week in San Francisco have shown.
More Articles...
- FDA Expands Harvoni Indication to Include Hepatitis C Genotypes 4-6 and HIV/HCV Coinfection
- AASLD 2015: Sofosbuvir/ Ledipasvir + Vedroprevir Cures 96% of Cirrhotic Genotype 1 Patients
- AASLD 2015: New AbbVie Hepatitis C Combination Cures Up to 97% with Genotype 3
- AASLD 2015: Sofosbuvir + Ravidasvir Shows High Response Rates for Genotype 4 Hepatitis C
Web Design and Development by